Showing results (191-200 of 270) with videos related to

Sort By:
Pageof 27
Frontiers in Oncology|February 21, 2022
Corrigendum: Results of the ECHO (Eating habits CHanges in Oncologic patients) Survey: An Italian Cross-Sectional Multicentric Study to Explore Dietary Changes and Dietary Supplement Use, in Breast Cancer SurvivorsGreta Caprara, Maria Tieri, Alessandra Fabi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2012
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB studyValentina Guarneri, Antonio Frassoldati, Alberto Bottini, et al.
Frontiers in Oncology|November 22, 2021
Results of the ECHO (Eating habits CHanges in Oncologic patients) Survey: An Italian Cross-Sectional Multicentric Study to Explore Dietary Changes and Dietary Supplement Use, in Breast Cancer SurvivorsGreta Caprara, Maria Tieri, Alessandra Fabi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 25, 2023
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized TrialPierFranco Conte, Giancarlo Bisagni, Federico Piacentini, et al.
Breast (Edinburgh, Scotland)|March 17, 2024
Gender minorities in breast cancer - Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patientsFederica Miglietta, Letizia Pontolillo, Carmine De Angelis, et al.
Future Oncology (London, England)|May 14, 2021
Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further linesAlessandro Dal Maso, Martina Lorenzi, Alessandra Ferro, et al.
Therapeutic Advances in Medical Oncology|March 20, 2023
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapyGiovanna Garufi, Luisa Carbognin, Isabella Sperduti, et al.
Cancer Treatment Reviews|August 28, 2023
Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spreadCarmen Criscitiello, Chiara Corti, Michelino De Laurentiis, et al.
The Oncologist|April 16, 2022
Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving NivolumabGiulia Pasello, Martina Lorenzi, Lorenzo Calvetti, et al.
Clinical Lung Cancer|June 17, 2026
CHIMERA: A Phase II Study of Neoadjuvant Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed Followed by Surgery and Adjuvant Pembrolizumab in Resectable Pleural MesotheliomaGiulia Pasello, Daniela Scattolin, Eleonora Faccioli, et al.
Pageof 27